pembrolizumab   Click here for help

GtoPdb Ligand ID: 7499

Synonyms: Keytruda® | lambrolizumab | MK-3475
Approved drug Immunopharmacology Ligand
pembrolizumab is an approved drug (FDA (2014), EMA (2015))
Compound class: Antibody
Comment: Pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.

Pembrolizumab is the first immuno-oncology therapeutic to be approved for use in cancers of any tissue type, so long as they express a specific genetic biomarker (i.e. high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumours). This is an important breakthrough, since up until this point FDA approvals, including earlier approvals for pembrolizumab, had always been restricted to certain tissue-specific cancers.
Click here for help
References
1. Carven GJ, Van Eenennaam H, Dulos GJ. (2010)
Antibodies to human programmed death receptor PD-1.
Patent number: US20100266617. Assignee: Organon NV. Priority date: 13/06/2008. Publication date: 21/10/2010.
2. FDA. 
FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL.
Accessed on 18/06/2018. Modified on 18/06/2018. FDA.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610670.htm?utm_campaign=Oncology%206%2F13%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=ce3e8cb7b99142cba3cc1d7c54d4ca4b&elq=7a1e38bda6884f40bcc462e71a154a89&elqaid=3898&elqat=1&elqCampaignId=3025
3. FDA. 
FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma.
Accessed on 23/04/2019. Modified on 23/04/2019. fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm636395.htm
4. Greaves P, Gribben JG. (2013)
The role of B7 family molecules in hematologic malignancy.
Blood, 121 (5): 734-44. [PMID:23223433]
5. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al.. (2013)
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N Engl J Med, 369 (2): 134-44. [PMID:23724846]
6. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012)
T cell coinhibition and immunotherapy in human breast cancer.
Discov Med, 14 (77): 229-36. [PMID:23114578]
7. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP et al.. (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
N Engl J Med, 374 (26): 2542-52. [PMID:27093365]
8. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A et al.. (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
N Engl J Med, 379 (21): 2040-2051. [PMID:30280635]
9. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B et al.. (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med, 380 (12): 1116-1127. [PMID:30779529]
10. Saada-Bouzid E, Peyrade F, Guigay J. (2019)
Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Curr Opin Oncol, 31 (3): 146-151. [PMID:30893146]
11. Tang PA, Heng DY. (2013)
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.
Curr Oncol Rep, 15 (2): 98-104. [PMID:23263823]